|Bid||3.89 x 1300|
|Ask||4.00 x 800|
|Day's Range||3.9000 - 4.0570|
|52 Week Range||1.1200 - 4.3400|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||7.36|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Investors need to pay close attention to Aeterna Zentaris (AEZS) stock based on the movements in the options market lately.
Aeterna Zentaris Inc. (AEZS) (AEZS) announced that the European Medicines Agency (EMA) has granted marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). “Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition,” said Dr. Christian Strasburger, the Head of Clinical Endocrinology at Charité Unversitaetsmedizin Berlin and the principal investigator for macimorelin. AGHD may occur in an adult subject who has a history of childhood onset growth hormone deficiency (GHD) or may occur during adulthood as an acquired condition.
CHARLESTON, S.C., Dec. 21, 2018 -- Aeterna Zentaris Inc., (NASDAQ:AEZS) (TSX: AEZS) has settled its previously disclosed litigation in South Carolina and Canada with former.
In the latest trading session, Aeterna Zentaris (AEZS) closed at $2.90, marking a +1.75% move from the previous day.
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
Aeterna Zentaris Inc. (AEZS) (AEZS), announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). The recommendation will now be reviewed by the European Commission. “We are pleased with the CHMP’s positive opinion of macimorelin for AGHD,” said Michael V. Ward, Chief Executive Officer of Aeterna Zentaris.
CORAL GABLES, FL / ACCESSWIRE / November 16,2018 / There's no denying the progress that the healthcare industry has made. According to analyst firm Market Research Engine, the E-Health Market is expected to exceed more than US$136 Billion by 2024 at a CAGR of 21% in the given forecast period. Bank of America surveyed** 225 fund managers with $641 billion in assets under management, who said the most "crowded trade" is in tech stocks.
The Summerville, South Carolina-based company said it had a loss of 15 cents per share. The drug developer posted revenue of $663,000 in the period. In the final minutes of trading on Tuesday, the company's ...
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. In intra-day trading on October 31, 2018, Aeterna Zentaris is at $2.11 per share (+62.31%) in reaction to Strongbridge Biopharma's out-licensing deal with Novo Nordisk for U.S. and Canadian rights to the AEZS drug MACRILEN (macimorelin). Details of the Macrilen™ and the Novo Nordisk deal and analysts review here READ MORE.
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Aeterna Zentaris saw its shares climbing as Wall Street learned about Novo Nordisk and Strongbridge Biopharma’s deal where Aeterna Zentaris stands to capitalize. ...